Geoffrey Hsu
Director/Board Member presso THE BIOTECH GROWTH TRUST PLC
Provenienza dei contatti di primo grado di Geoffrey Hsu
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.
100
| Subsidiary | Investment Managers | 100 |
OrbiMed Advisors LLC
 OrbiMed Advisors LLC Investment ManagersFinance OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds.
53
| Private Company | Investment Managers | 53 |
| Mutual Fd-Closed End | Investment Trusts/Mutual Funds | 9 | |
OrbiMed Capital LLC
 OrbiMed Capital LLC Financial ConglomeratesFinance Part of OrbiMed Advisors LLC, OrbiMed Capital LLC is a private company based in New York, NY.
4
| Subsidiary | Financial Conglomerates | 4 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Geoffrey Hsu tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| MORGAN STANLEY | Investment Managers | Corporate Officer/Principal Private Equity Analyst | |
| INTERCEPT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| GLAUKOS CORPORATION | Medical Specialties | Director/Board Member Director/Board Member | |
| GELESIS INC | Biotechnology | Director/Board Member Chairman Director/Board Member | |
Cerapedics, Inc.
 Cerapedics, Inc. Pharmaceuticals: MajorHealth Technology Cerapedics, Inc. engaged in the provision of developing and commercializing novel osteobiologic products. It offers i-FACTOR Bone Graft, an advanced biologic that supported with level I evidence, and provides benefit ratio. The company was founded by Andrew J. Tofe and is headquartered in Westminster, CO. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| TURG POIN | Pharmaceuticals: Major | Director/Board Member Chairman | |
| Brown University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| The Trustees of Columbia University in The City of New York | College/University | Undergraduate Degree Doctorate Degree | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Masters Business Admin Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Stanford University | College/University | Graduate Degree Graduate Degree | |
| University of Pennsylvania | College/University | Corporate Officer/Principal Masters Business Admin | |
JPMorgan Elect Plc
 JPMorgan Elect Plc Finance/Rental/LeasingFinance JPMorgan Elect Plc is a closed-end investment company. It offers three investment choices: Managed Growth, Managed Income, and Managed Cash. The Managed Growth includes long term capital growth from investing in a range of investment trusts and open-ended funds. The Managed Income comprises growth of income with potential for a long term capital growth by investing primarily in UK equities. The Managed Cash invests primarily in GBP denominated short-term debt securities. The company was founded on September 16, 1999 and is headquartered in London, the United Kingdom. | Finance/Rental/Leasing | Director/Board Member Chairman | |
Goldman Sachs & Co. LLC
 Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Financial Conglomerates | Analyst-Equity Corporate Officer/Principal Corporate Officer/Principal | |
| University of Oxford | College/University | Graduate Degree Corporate Officer/Principal Doctorate Degree Graduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Emory University | College/University | Undergraduate Degree Masters Business Admin | |
| Yale University | College/University | Graduate Degree Graduate Degree Doctorate Degree | |
| New York University | College/University | Masters Business Admin Undergraduate Degree Corporate Officer/Principal Masters Business Admin | |
| Princeton University | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
| University College Dublin | College/University | Undergraduate Degree Undergraduate Degree | |
| INSULET CORPORATION | Medical Specialties | Director/Board Member Director/Board Member | |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| FORTRESS INVESTMENT GROUP LLC | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal Chief Executive Officer | |
Genome Research Ltd.
 Genome Research Ltd. Miscellaneous Commercial ServicesCommercial Services Part of The Wellcome Trust Ltd., Genome Research Ltd. is a world-leading genomics research institute founded in 1992. The private company is based in Cambridge, UK. Genome Research delivers therapeutic, diagnostic, and production benefits in areas such as cancer, immunology, public health, and personalized treatment. The British company tackle some of the most difficult challenges in genomic research, demanding science at scale and a visionary and creative approach to research that pushes the boundaries of our understanding in ever new and exciting ways. The company's work helps improve human health and understand life on a molecular level. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| JPMORGAN ELECT PLC - MANAGED GROWTH | Investment Trusts/Mutual Funds | Director/Board Member Chairman | |
| JPMORGAN FLEMING ELECT-MGD | Investment Trusts/Mutual Funds | Director/Board Member Chairman | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Graduate Degree | |
| Harvard College | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| INTELLIA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| XTANT MEDICAL HOLDINGS, INC. | Medical Specialties | Chairman Director/Board Member Director/Board Member | |
Adicet Therapeutics, Inc.
 Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| ORIC PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Attenua, Inc.
 Attenua, Inc. Pharmaceuticals: MajorHealth Technology Attenua, Inc. engages in the provision of biopharmaceutical services. The company was founded by Jing Liang and is headquartered in San Mateo, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| IKENA ONCOLOGY, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| PREVAIL THERAPEUTICS INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| THESEUS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Chief Executive Officer | |
Perfuse Therapeutics, Inc.
 Perfuse Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Perfuse Therapeutics, Inc. operates as biotechnology company that focuses on retinal perfusion. The company was founded by Sevgi Gurkan in 2018 and is headquartered in San Francisco,CA. | Miscellaneous Commercial Services | Director/Board Member Founder | |
Emendo Biotherapeutics, Inc.
 Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | Biotechnology | Director/Board Member Director/Board Member | |
| GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ADARx Pharmaceuticals, Inc.
 ADARx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services ADARx Pharmaceuticals, Inc. operates as RNA base-editing company. The company is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Odyssey Therapeutics, Inc.
 Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | Packaged Software | Director/Board Member Director/Board Member | |
Immpact Bio USA, Inc.
 Immpact Bio USA, Inc. BiotechnologyHealth Technology ImmPACT Bio USA, Inc. operates as a cell therapy company. The firm develops potent and selective engineered T-cells for the treatment of solid tumors. The company is headquartered in Camarillo, CA. | Biotechnology | Director/Board Member Chairman Director of Finance/CFO | |
| ADICET BIO, INC. | Pharmaceuticals: Major | Chairman Director/Board Member Director of Finance/CFO | |
| WORLDWIDE HEALTHCARE TRUST PLC | Investment Trusts/Mutual Funds | Director/Board Member Director/Board Member Director/Board Member | |
Gwynant Therapeutics
 Gwynant Therapeutics Pharmaceuticals: MajorHealth Technology Gwynant Therapeutics develops new small molecules for oncology targets. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Charm Therapeutics Ltd.
 Charm Therapeutics Ltd. BiotechnologyHealth Technology Charm Therapeutics Ltd. is a British London-based company that is discovering and developing small molecule medicines using its proprietary 3D deep learning-enabled platform, Dragonfold. The company aims to create life-changing therapies for difficult-to-drug targets in cancer and other disease areas. Charm Therapeutics has raised $70 million to date and is supported by high-quality international investors, including Orbimed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA, and Grep-VC. The company was founded in 2021 by Laksh Aithani and David Baker, with Laksh Aithani serving as the CEO since then. | Biotechnology | Director/Board Member Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 40 |
| Regno Unito | 8 |
| Canada | 3 |
| Irlanda | 2 |
| Danimarca | 2 |
Settori
| Health Technology | 27 |
| Consumer Services | 14 |
| Finance | 5 |
| Commercial Services | 4 |
| Miscellaneous | 4 |
Posizioni
| Director/Board Member | 462 |
| Independent Dir/Board Member | 142 |
| Corporate Officer/Principal | 132 |
| Undergraduate Degree | 89 |
| Private Equity Investor | 87 |
Contatti più connessi
| Insiders | |
|---|---|
| Carl Gordon | 59 |
| Jonathan Silverstein | 42 |
| Peter Thompson | 39 |
| Chau Khuong | 38 |
| Erez Chimovits | 30 |
| Iain Dukes | 30 |
| Joseph Zakrzewski | 30 |
| Rishi Gupta | 29 |
| David Willetts | 29 |
| Sunny Sharma | 29 |
| Guo-Liang Yu | 27 |
| Roger Yates | 27 |
| David Bonita | 27 |
| Steve Bates | 25 |
| Dina Chaya | 23 |
- Borsa valori
- Insiders
- Geoffrey Hsu
- Connessioni Società
